U.S. Real World Evidence Solutions Market Size, Share & Industry Analysis, By Type (Clinical Setting Data, Claims Data, Pharmacy Data, Patient Powered Data, and Others), By End-user (Pharmaceutical and Medical Device Companies, Healthcare Payers, Healthcare Providers, and Others), and Country Forecast, 2024-2032

1. Introduction
   1. Research Scope
   2. Market Segmentation
   3. Research Methodology
   4. Definitions & Assumptions
2. Executive Summary
3. Market Dynamics
   1. Market Drivers
   2. Market Restraints
   3. Market Opportunities
   4. Market Trends
4. Key Insights
   1. Number of Clinical Trials Conducted in the U.S.
   2. Key Industry Developments (Mergers, Acquisitions, Collaborations, etc.)
   3. Impact of COVID-19 on the Market
5. U.S. Real World Evidence Solutions Market Analysis, Insights and Forecast, 2019-2032
   1. Market Analysis, Insights and Forecast – By Type
      1. Clinical Setting Data
      2. Claims Data
      3. Pharmacy Data
      4. Patient Powered Data
      5. Others
   2. Market Analysis, Insights and Forecast – By End User
      1. Pharmaceutical and Medical Device Companies
      2. Healthcare Payers
      3. Healthcare Providers
      4. Others
6. Competitive Analysis
   1. U.S. Market Share Analysis (2023)
   2. Company Profiles
      1. IQVIA, Inc.
         1. Overview
         2. Products
         3. SWOT Analysis
         4. Recent Developments
         5. Strategies
         6. financials (Based on Availability)
      2. IBM
         1. Overview
         2. Products
         3. SWOT Analysis
         4. Recent Developments
         5. Strategies
         6. financials (Based on Availability)
      3. Cognizant
         1. Overview
         2. Products
         3. SWOT Analysis
         4. Recent Developments
         5. Strategies
         6. financials (Based on Availability)
      4. Oracle
         1. Overview
         2. Products
         3. SWOT Analysis
         4. Recent Developments
         5. Strategies
         6. financials (Based on Availability)
      5. Syneos Health
         1. Overview
         2. Products
         3. SWOT Analysis
         4. Recent Developments
         5. Strategies
         6. financials (Based on Availability)
      6. Optum, Inc. (UnitedHealth Group)
         1. Overview
         2. Products
         3. SWOT Analysis
         4. Recent Developments
         5. Strategies
         6. financials (Based on Availability)
      7. Flatiron Health (F. Hoffmann-La Roche Ltd.)
         1. Overview
         2. Products
         3. SWOT Analysis
         4. Recent Developments
         5. Strategies
         6. financials (Based on Availability)
      8. Thermo Fisher Scientific Inc.
         1. Overview
         2. Products
         3. SWOT Analysis
         4. Recent Developments
         5. Strategies
         6. financials (Based on Availability)
      9. Parexel International Corporation
         1. Overview
         2. Products
         3. SWOT Analysis
         4. Recent Developments
         5. Strategies
         6. financials (Based on Availability)
      10. SAS Institute, Inc.
          1. Overview
          2. Products
          3. SWOT Analysis
          4. Recent Developments
          5. Strategies
          6. financials (Based on Availability)
      11. PerkinElmer, Inc.
          1. Overview
          2. Products
          3. SWOT Analysis
          4. Recent Developments
          5. Strategies
          6. financials (Based on Availability)

List of Figures:

Figure 1: U.S. Real World Evidence Solutions Market Revenue Breakdown (USD Billion, %), By Type, 2023 & 2032

Figure 2: U.S. Real World Evidence Solutions Market Value Share (%), by Type, 2023 & 2032

Figure 3: U.S. Real World Evidence Solutions Market Value Share (%), by End User, 2023 & 2032

Figure 4: U.S. Real World Evidence Solutions Market Share (%), By Company, 2023

List of Tables:

Table 1: U.S. Real World Evidence Solutions Market Revenue (USD Billion) Forecast, by Type, 2019–2032

Table 2: U.S. Real World Evidence Solutions Market Revenue (USD Billion) Forecast, by End User, 2019–2032